Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in septic ICU patients
IRCT20240804062637N2Phase 3Recruiting
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sepsis comparing Empagliflozin with Placebo (2 arms). Primary endpoints: Incidence of acute kidney injury and Mortality. Started Apr 2026; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
sepsis
Beyond the preview
Go deeper on IRCT20240804062637N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240804062637N2.